Monoclonal antibody LY-COV555

Ended Definitive Contract Awarded Last action

Contract number
W911QY21C0016
Awardee
Awarding agency
Obligated
$1,373,930,000

Award facts

Opportunity
  • W911QY21R0016 Solicitation number
  • W911QY-21-c-0016 Limited / Sole Source Justification · Posted Nov 25, 2020
Contract value 100% obligated
$1,373,930,000.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Funding agency
Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
Set-aside
No set-aside
Competition
Not Competed · 1 offer Only One Source
Pricing
Firm Fixed Price
Place of performance
Indianapolis, IN 46285, USA
Legislative mandates
National interest action
Coronavirus COVID-19

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00008 · Monoclonal antibody LY-COV555 - modification to descope quantity of subclin 0001 05, deobligate excess funds from acrn ad, change POP of contract, and… -$438,570,000
Funding Only Action P00007 · Modification to add incremental funding via subclin 0001 05. $625,000,000
Supplemental Agreement for work within scope P00006 · Modification to change the maximum QTY from 950,000 doses of the monoclonal antibody LY-COV555 to 3,000,000 doses. $0
Funding Only Action P00005 · Modification to add incremental funding via subclin 0001 04. $375,000,000
Funding Only Action P00004 · Modification to add incremental funding via subclin 0001 03. $437,500,000
Other Administrative Action P00003 · Modification to add hrpas rating to contract. $0
Other Administrative Action P00002 · Admin modification to change inspect by dodaac to W911QY in wawf clause 252.232-7006. $0
Funding Only Action P00001 · Add incremental funding via subclin 0001 02 and correct pay office dodaac. $62,500,000
Original award $312,500,000

About this award

Written by GovTribe AI ·

The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a definitive contract valued at approximately $1.4 billion to Eli Lilly and Company. The firm fixed price contract is for the delivery of monoclonal antibody LY-COV555 to address the Coronavirus COVID-19 national interest. Performance will occur at Eli Lilly's facility in Indianapolis, Indiana over an approximately 8 month period concluding in June 2021. No set aside designation or subcontractors were indicated. The Support Center, a component of the Army focused on chemical and biological defense programs, is providing the funding in support of the government's response to the COVID-19 pandemic through this substantial contract for monoclonal antibody supplies.

Quick answers

Who was awarded contract W911QY21C0016?

W911QY21C0016 was awarded to ELI Lilly And Company by ACC Aberdeen Proving Ground (Army Contracting Command) on October 27, 2020.

How much is contract W911QY21C0016 worth?

The government has obligated $1,373,930,000 on W911QY21C0016.

Which agency awarded contract W911QY21C0016?

ACC Aberdeen Proving Ground (Army Contracting Command) awarded W911QY21C0016, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).

Was contract W911QY21C0016 competed?

The extent of competition for W911QY21C0016 was not competed. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login